Harigai, Masayoshi http://orcid.org/0000-0002-6418-2603
Tanaka, Eiichi http://orcid.org/0000-0003-2850-326X
Inoue, Eisuke http://orcid.org/0000-0002-1652-7769
Sakai, Ryoko http://orcid.org/0000-0002-1640-1373
Sugitani, Naohiro http://orcid.org/0000-0003-2069-5500
Toyoizumi, Shigeyuki http://orcid.org/0000-0002-7011-5263
Sugiyama, Naonobu http://orcid.org/0000-0002-5008-0665
Yamanaka, Hisashi http://orcid.org/0000-0001-8453-6731
Funding for this research was provided by:
Pfizer Japan
Article History
Received: 22 February 2024
Accepted: 29 May 2024
First Online: 17 July 2024
Declarations
:
: Masayoshi Harigai has received research grants from AbbVie Japan GK, Asahi Kasei Corp., Boehringer Ingelheim Japan, Inc., Eli Lilly Japan K.K., Kaken Pharmaceutical Co., Mitsubishi Tanabe Pharma Co., Mochida Pharmaceutical Co., Nippon Shinyaku Co., Ltd., Taisho Pharmaceutical Co., Ltd., Teijin Pharma Ltd., UCB Japan Co., Ltd., and Viatris Japan; speaker fees from AbbVie Japan GK, Asahi Kasei Corp., Ayumi Pharmaceutical Co., Boehringer Ingelheim Japan, Inc., Bristol Myers Squibb Co., Ltd., Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Eli Lilly Japan K.K., Gilead Sciences Inc., Janssen Pharmaceutical K.K., Kissei Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Co., Mochida Pharmaceutical Co., Ltd., Nippon Kayaku Co., Ltd., Nippon Shinyaku Co., Ltd., Ono Pharmaceutical Co., Ltd., Taisho Pharmaceutical Co., Ltd., Teijin Pharma Ltd, and UCB Japan; and has acted as a consultant for AbbVie, Boehringer Ingelheim, Bristol Myers Squibb Co., Ltd., and Teijin Pharma. Masayoshi Harigai was an employee of Tokyo Women’s Medical University School of Medicine at the time of this study and is now employed at Sanno Hospital and International University of Health and Welfare. Eiichi Tanaka is a member of the speakers’ bureau for AbbVie Japan GK, Asahi Kasei Corp., Astellas Pharma Inc., Ayumi Pharmaceutical Co., Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Eli Lilly Japan K.K., GlaxoSmithKline K.K., Janssen Pharmaceutical K.K., Kyowa Pharma Chemical Co., Ltd., Mochida Pharmaceutical Co., Ltd., Pfizer Japan Inc, Takeda Pharmaceutical Co., Ltd., and Teijin Pharma Ltd; has received lecture fees or consulting fees from AbbVie Japan GK, Asahi Kasei Corp., Astellas Pharma Inc., Ayumi Pharmaceutical Co., Boehringer Ingelheim Japan, Inc., Bristol Myers Squibb Co., Ltd., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo, Inc., Eisai Co., Ltd., Eli Lilly Japan K.K., Gilead Sciences, Inc., GlaxoSmithKline K.K., Janssen Pharmaceutical K.K., Kyowa Pharma Chemical Co., Ltd., Mitsubishi Tanabe Pharma Co., Mochida Pharmaceutical Co., Ltd., Nippon Kayaku Co., Ltd., Pfizer Japan Inc, Takeda Pharmaceutical Co., Ltd., Teijin Pharma Ltd, and Viatris Inc; and has received research funding from Pfizer Inc and UCB Japan Co. Ltd. Eisuke Inoue is a member of the speakers’ bureau for Bristol Myers Squibb and Pfizer Japan Inc, and has received consulting fees from Nippontect Systems Co., Ltd. Ryoko Sakai is a member of the speakers’ bureau for Bristol Myers Squibb. Naohiro Sugitani declares that they have no competing interests. Shigeyuki Toyoizumi is an employee of Pfizer R&D Japan. Naonobu Sugiyama is an employee and shareholder of Pfizer Japan Inc. Hisashi Yamanaka is a member of the speakers’ bureau for Teijin Pharma Ltd and YLBio, and has received speaker or consultant fee from Astellas, Bristol Myers Squibb, CorEvitas, LLC, Eisai, Pfizer, Mitsubishi Tanabe, Teijin Pharma, and YLBio.
: Comprehensive patient consent was obtained at enrollment into the IORRA patient registry [], and consent for data to be used for studies involving the IORRA patient registry was obtained at each survey. Informed consent for this specific study was not required, although an opt-out approach to consent was used. The final protocol, any amendments, and informed consent documentation were approved by the IORRA committee (reference number: 2922-R16).